Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DECIBEL THERAPEUTICS INC (DBTX) Stock Price & Overview
NASDAQ:DBTX • US24343R1068
Current stock price
4.91 USD
-0.04 (-0.81%)
At close:
4.91 USD
0 (0%)
After Hours:
The current stock price of DBTX is 4.91 USD. Today DBTX is down by -0.81%. In the past month the price decreased by -4.1%. In the past year, price increased by 28.53%.
DBTX Key Statistics
52-Week Range1.61 - 5.4
Current DBTX stock price positioned within its 52-week range.
1-Month Range4.88 - 5.26
Current DBTX stock price positioned within its 1-month range.
- Market Cap
- 123.388M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.53
- Dividend Yield
- N/A
DBTX Stock Performance
Today
-0.81%
1 Week
-3.73%
1 Month
-4.10%
3 Months
+23.37%
Longer-term
6 Months +85.28%
1 Year +28.53%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
DBTX Stock Chart
DBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DBTX. When comparing the yearly performance of all stocks, DBTX is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DBTX. DBTX has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DBTX Earnings
Next Earnings DateNov 7, 2023
Last Earnings DateAug 11, 2023
PeriodQ2 / 2023
EPS Reported-$0.73
Revenue Reported
EPS Surprise -30.24%
Revenue Surprise -100.00%
DBTX Forecast & Estimates
10 analysts have analysed DBTX and the average price target is 7.78 USD. This implies a price increase of 58.4% is expected in the next year compared to the current price of 4.91.
For the next year, analysts expect an EPS growth of -15% and a revenue growth -100% for DBTX
Analysts
Analysts78
Price Target7.78 (58.45%)
EPS Next Y-15%
Revenue Next Year-100%
DBTX Financial Highlights
Over the last trailing twelve months DBTX reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -9.05% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-63.39M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-7.35%
Sales Q2Q%N/A
EPS 1Y (TTM)-9.05%
Revenue 1Y (TTM)N/A
DBTX Ownership
Ownership
Inst Owners0.16%
Shares25.13M
Float21.79M
Ins Owners9.14%
Short Float %N/A
Short RatioN/A
DBTX Industry Overview
DBTX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
DBTX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.56 | 349.666B | ||
| AMGN | AMGEN INC | 14.67 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.55 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.7 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.63 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.4 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.81 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.57 | 24.944B | ||
| INCY | INCYTE CORP | 10.76 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DBTX
Company Profile
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Company Info
IPO: 2021-02-12
DECIBEL THERAPEUTICS INC
1325 Boylston Street, Suite 500
Boston MASSACHUSETTS 02215 US
CEO: Laurence Reid
Employees: 68
Phone: 16173708701.0
DECIBEL THERAPEUTICS INC / DBTX FAQ
Can you describe the business of DECIBEL THERAPEUTICS INC?
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
What is the stock price of DECIBEL THERAPEUTICS INC today?
The current stock price of DBTX is 4.91 USD. The price decreased by -0.81% in the last trading session.
Does DBTX stock pay dividends?
DBTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DBTX stock?
DBTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is DECIBEL THERAPEUTICS INC (DBTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DBTX.
Can you provide the growth outlook for DECIBEL THERAPEUTICS INC?
The Revenue of DECIBEL THERAPEUTICS INC (DBTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of DBTX stock?
DECIBEL THERAPEUTICS INC (DBTX) has a market capitalization of 123.39M USD. This makes DBTX a Micro Cap stock.